Stock market today: S&P 500 falls as government shutdown, trade jitters persist
Investing.com - Wells Fargo has raised its price target on Abbott Labs (NYSE:ABT) to $146.00 from $142.00 while maintaining an Overweight rating following the company’s third-quarter earnings report. According to InvestingPro data, Abbott Labs, currently valued at $225.3 billion, is trading slightly below its Fair Value, with analysts setting targets ranging from $122 to $159.
Abbott reported quarterly sales of $11.37 billion on October 15, approximately in line with consensus estimates of $11.4 billion, with organic growth excluding COVID testing reaching 7.5%. The company maintains strong financial metrics, with InvestingPro analysis showing a healthy P/E ratio of 16.7 and impressive trailing twelve-month revenue of $43.8 billion. Get access to 8 more exclusive InvestingPro Tips and comprehensive financial analysis through the Pro Research Report.
The company’s Medtech division showed particular strength, growing 12.5% and exceeding Wells Fargo’s estimate of 11.0%, while the Established Pharmaceuticals Division (EPD) grew 7.1%, also beating expectations of 6.5%.
Nutrition grew 4.7%, slightly below the expected 5.0%, while Core Diagnostics grew just 0.4% against an anticipated 2.1%, with the latter impacted by ongoing value-based purchasing headwinds in China and a slow start to seasonal respiratory testing.
Abbott has reiterated its organic sales growth guidance for 2025 while tightening its earnings per share forecast, with the company expressing comfort with previous Street estimates for 2026.
In other recent news, Abbott Laboratories reported its third-quarter 2025 earnings, aligning with analysts’ expectations with an earnings per share (EPS) of $1.30. However, the company slightly missed revenue forecasts, reporting $11.37 billion against the anticipated $11.4 billion. This revenue shortfall led to some investor concerns regarding future growth prospects. In addition, Jefferies raised its price target for Abbott Labs to $146 from $141, maintaining a Buy rating. The firm highlighted the accelerating growth in Abbott’s medical device segment, which accounts for about 50% of the company’s sales. This segment is noted for operating at higher margins than other divisions and exceeding estimates. Jefferies pointed out that a robust pipeline of new products contributes to this growth. These developments provide a snapshot of Abbott Labs’ current financial and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.